Roche’s Enspryng (satralizumab) Receives Health Canada Approval for Neuromyelitis Optica Spectrum Disorder

 Roche’s Enspryng (satralizumab) Receives Health Canada Approval for Neuromyelitis Optica Spectrum Disorder

Roche’s Enspryng (satralizumab) Receives Health Canada Approval for Neuromyelitis Optica Spectrum Disorder

Shots:

  • The approval is based on two P-III studies: The SAkuraStar & SAkuraSky studies involves assessing Enspryng as monothx.  and in combination with IST vs PBO in 95 & 83 NMOSD patients who are AQP4 seropositive aged 18-74yrs. & 12-74yrs. respectively
  • SAkuraStar & SAkuraSky results: 74% & 79% reduction in the risk of relapses respectively
  • Enspryng (SC, q4w) is a mAb targeting IL-6R treatment. Additionally, Canada is the first country to receive health authority approval for Enspryng, offering a new treatment option for NMOSD  

Click here ­to­ read full press release/ article | Ref: Newswire Canada | Image: Dealbook

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post